FILE PHOTO: Laura Ng, who has lupus and had to recently call at least five pharmacies before she could find a place to fill her hydroxychloroquine prescription, is photographed in Seattle, Washington, U.S. March 31, 2020. Ng said she is worried about the supply due to interest in the drug as a treatment for coronavirus disease (COVID-19). REUTERS/Lindsey Wasson
GENEVA (Reuters) – A clinical trial of malaria drug hydroxychloroquine in COVID-19 patients has been suspended amid safety concerns, World Health Organization (WHO Director General Tedros Adhanom Ghebreyesus said on Monday.
“The executive group has implemented a temporary pause of the hydroxychloroquine arm within the Solidarity trial while the safety data is reviewed by the data safety monitoring board. The other arms of the trial are continuing,” Tedros told an online briefing.
Reporting by Michael Shields; editing by John Stonestreet
View original article here Source